All patients also underwent MIBG imaging, with planar and SPECT tomographic imaging performed delayed at 21 ± 2 h (range 17–24 hour) after injection of 259 ± 92 MBq (range 151–392 MBq) and within 7 ± 7 days (range < 1–23 days) prior to MFBG PET. The scans were performed on the Philips Precedence (Koninklijke Philips N.V.) or Discovery D670 (GE Healthcare, Inc.) and included whole-body planar imaging and SPECT/CT of the chest, abdomen, and pelvis. SPECT data were acquired for a total of 40–50 minutes (20–25 sec per step, 120 steps of 3° each).
Discovery d670
Manufactured by GE Healthcare
The Discovery D670 is a laboratory equipment product from GE Healthcare. It is a diagnostic imaging system designed for a range of applications in medical research and clinical settings. The core function of the Discovery D670 is to provide high-quality imaging capabilities to support various diagnostic and research activities.
Automatically generated - may contain errors
Lab products found in correlation
2 protocols using discovery d670
1
MIBG and MFBG PET Imaging for Neuroendocrine Tumors
2
Triple-Phase Contrast-Enhanced Imaging Protocol
Check if the same lab product or an alternative is used in the 5 most similar protocols
+ Expand
Triple-phase contrast-enhancement CT (GE Healthcare LightSpeed VCT) and T2-weighted fat-saturated MR images (GE Healthcare Signa 3T) were acquired 11-48 d before treatment (baseline), SPECT/ CT images were acquired 1 d after treatment, and follow-up CT and MR images were acquired 8-12 wk later. Manual registration of baseline CT and MR images to SPECT/CT was performed using Hybrid-Viewer software (version 2.6F; Hermes). SPECT/CT scans were acquired on a dual-head g-camera (GE Healthcare Discovery D670) by imaging bremsstrahlung radiation with an energy window of 50-150 keV using a medium-energy general-purpose collimator, a 128 • 128 matrix, 90 views, and 20 s per view. The GE Healthcare default settings were used for SPECT/CT data reconstruction (scatter correction off, resolution recovery on, and attenuation correction on). Images were processed using Xeleris (version 3.0; GE Healthcare) with the default ordered-subset expectation maximization settings (2 iterations and 10 subsets).
Voxel-based gross tumor volumes were determined by crossreferencing CT sections with MR images to localize tumor boundaries and guide CT segmentation at baseline and at the 2 to 3 mo follow-up. To assess outcome, response was based on vRECIST, comparing relative change in tumor volume, defined as the ratio of the difference between tumor volume at baseline and after treatment to the baseline volume
Voxel-based gross tumor volumes were determined by crossreferencing CT sections with MR images to localize tumor boundaries and guide CT segmentation at baseline and at the 2 to 3 mo follow-up. To assess outcome, response was based on vRECIST, comparing relative change in tumor volume, defined as the ratio of the difference between tumor volume at baseline and after treatment to the baseline volume
About PubCompare
Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.
We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.
However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.
Ready to get started?
Sign up for free.
Registration takes 20 seconds.
Available from any computer
No download required
Revolutionizing how scientists
search and build protocols!